enGene (NASDAQ:ENGN) Upgraded to “Outperform” at Leerink Partners

Leerink Partners upgraded shares of enGene (NASDAQ:ENGN) from a market perform rating to an outperform rating in a research note published on Friday, Marketbeat Ratings reports. Leerink Partners currently has $5.00 price objective on the stock.

Several other research firms also recently issued reports on ENGN. Wells Fargo & Company raised shares of enGene from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $2.00 to $6.00 in a research report on Thursday. Jefferies Financial Group upgraded shares of enGene to a “strong-buy” rating in a report on Tuesday, October 13th. Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Piper Sandler raised shares of enGene from a “neutral” rating to an “overweight” rating and set a $4.00 price target on the stock in a research report on Thursday. Finally, Citizens Jmp reissued a “market perform” rating on shares of enGene in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.75.

enGene Stock Performance

enGene stock opened at $2.41 on Friday. The company has a current ratio of 10.21, a quick ratio of 10.21 and a debt-to-equity ratio of 0.11. enGene has a 12-month low of $1.40 and a 12-month high of $12.25. The business’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $3.97.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, sell-side analysts predict that enGene will post -1.82 earnings per share for the current year.

Institutional Trading of enGene

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. SR One Capital Management LP bought a new position in shares of enGene in the second quarter worth approximately $1,293,607. Eversept Partners LP increased its holdings in shares of enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock worth $3,477,000 after buying an additional 54,708 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after buying an additional 135,318 shares during the last quarter. Siren L.L.C. increased its holdings in shares of enGene by 57.5% in the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after buying an additional 1,916,895 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of enGene during the 1st quarter valued at $409,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.